This 2022 study investigates ivermectin's anticancer effects in prostate cancer, identifying FOXA1 and Ku70/Ku80 as direct targets. Ivermectin induces G0/G1 cell cycle arrest, apoptosis, and DNA damage, while suppressing androgen receptor (AR) signaling. It binds to FOXA1, reducing chromatin accessibility of AR signaling and E2F1, leading to inhibited cell proliferation.
